Payment overview · 2025
General Payments
$515.79
32 reported records · 12 companies
Healthcare provider profile · identity verified
Randy E Bowles, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JOPLIN, MO · NPI 1851332860
Verified facts
What the public records show
CMS Open Payments records show Randy E Bowles, M.D. received $515.79 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.07 | 15.9% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.93 | 12.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.47 | 11.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.39 | 9.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.37 | 9.0% | 3 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $44.97 | 8.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.03 | 7.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.35 | 7.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.22 | 7.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.15 | 6.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.63 | 3.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.21 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $515.79 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.07 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $62.93 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.47 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.39 | 3 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $44.97 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 561 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 420 | 104 |
| Methylprednisolone | Methylprednisolone | 346 | 215 |
| Lisinopril | Lisinopril | 259 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 60 |
| Alprazolam | Alprazolam | 208 | 36 |
| Losartan Potassium | Losartan Potassium | 198 | 49 |
| Gabapentin | Gabapentin | 190 | 45 |
| Tramadol Hcl | Tramadol Hcl | 182 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 43 |
| Azithromycin | Azithromycin | 168 | 121 |
| Meloxicam | Meloxicam | 160 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 33 |
| Omeprazole | Omeprazole | 145 | 36 |
| Furosemide | Furosemide | 134 | 43 |
| Trazodone Hcl | Trazodone Hcl | 122 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 81 |
| Montelukast Sodium | Montelukast Sodium | 108 | 28 |
| Potassium Chloride | Potassium Chloride | 105 | 29 |
| Metformin Hcl | Metformin Hcl | 104 | 31 |
| Simvastatin | Simvastatin | 99 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 20 |
| Donepezil Hcl | Donepezil Hcl | 95 | 17 |
| Allopurinol | Allopurinol | 93 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 25 |
| Lorazepam | Lorazepam | 86 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 24 |
| Glimepiride | Glimepiride | 80 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 25 |
| Sertraline Hcl | Sertraline Hcl | 74 | 19 |
| Carvedilol | Carvedilol | 72 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 19 |
| Eliquis | Apixaban | 67 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 16 |
| Famotidine | Famotidine | 64 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 14 |
| Atenolol | Atenolol | 57 | 13 |
| Prednisone | Prednisone | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 16 |
| Synthroid | Levothyroxine Sodium | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Ozempic | Semaglutide | 48 | 11 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Finasteride | Finasteride | 44 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Baclofen | Baclofen | 38 | 19 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 13 |
| Hydrocortisone | Hydrocortisone | 37 | 21 |
| Amoxicillin | Amoxicillin | 36 | 26 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 26 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $515.79 · 32 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CONTRAVE, Cologuard Collection Kit, EVENITY, FARXIGA, IBSRELA, NURTEC ODT, Ozempic, PROLIA, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VOWST, Veozah, XIFAXAN, ZAVZPRET, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error